Royalty Pharma (RPRX) Achieves Record Growth and Hits Investment Targets Ahead of Schedule

Financial Performance - Royalty Pharma reported a 16% increase in total portfolio receipts for 2025 and an 18% increase in Q4 alone [1][2] - The company achieved a 15.8% return on invested capital and met its five-year capital deployment target of $10 billion to $12 billion a year ahead of schedule [1][2] Strategic Transactions - The company completed $4.7 billion in transactions focused on attractive therapies and received positive clinical and regulatory milestones, including FDA approval of Myqorzo [2] - Management emphasized the growing importance of synthetic royalties as an alternative to traditional debt or equity financing for biotech firms [2] Future Outlook - Despite current momentum, Royalty Pharma is preparing for headwinds in 2026, including the loss of exclusivity for Promacta and the introduction of a biosimilar for Tysabri in the US market [3] - The company expects portfolio receipts in 2026 to range between $3.275 billion and $3.425 billion, indicating a modest growth forecast of 3% to 8% [3]